Search

Your search keyword '"Callea, V"' showing total 290 results
Start Over Author "Callea, V" Publication Year Range Last 50 years
290 results on '"Callea, V"'

1. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival

Author

Ferrero, S, Ladetto, M, Drandi, D, Cavallo, F, Genuardi, E, Urbano, M, Caltagirone, S, Grasso, M, Rossini, F, Guglielmelli, T, Cangialosi, C, Liberati, A M, Callea, V, Carovita, T, Crippa, C, De Rosa, L, Pisani, F, Falcone, A P, Pregno, P, Oliva, S, Terragna, C, Musto, P, Passera, R, Boccadoro, M, and Palumbo, A

Published
2015
Full Text
View/download PDF

2. Circulating miRNA markers show promise as new prognosticators for multiple myeloma

Author

Rocci, A, Hofmeister, C C, Geyer, S, Stiff, A, Gambella, M, Cascione, L, Guan, J, Benson, D M, Efebera, Y A, Talabere, T, Dirisala, V, Smith, E M, Omedè, P, Isaia, G, De Luca, L, Rossi, D, Gentili, S, Uccello, G, Consiglio, J, Ria, R, Benevolo, G, Bringhen, S, Callea, V, Weiss, B, Ferro, A, Magarotto, V, Alder, H, Byrd, J C, Boccadoro, M, Marcucci, G, Palumbo, A, and Pichiorri, F

Published
2014
Full Text
View/download PDF

8. Superiority of VTD over TD Incorporated Into ASCT for Newly Diagnosed MM: A451

Author

Cavo, M, Zambello, R, Nozzoli, C, Gugliotta, L, Pantani, L, Patriarca, F, Petrucci, M T, Tacchetti, P, Galli, M, Ceccolini, M, Di Raimondo, F, Rossi, G, Zamagni, E, Bringhen, S, Narni, F, Tosi, P, Montefusco, V, Offidani, M, Brioli, A, Pallotti, M C, Spadano, T, Pescosta, N, Goldaniga, M, Ledda, A, Perrone, G, Petrucci, A, Caravita, T, Cascavilla, N, Gherlinzoni, F, De Stefano, V, Angelucci, E, Petti, M C, Ballanti, S, Callea, V, and Baccarani, M

Published
2009

15. Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group

Author

Zucca, E., Conconi, A., Mughal, T.I., Sarris, A.H., Seymour, J.F., Vitolo, U., Klasa, R., Ozsahin, M., Mead, G.M., Gianni, M.A., Cortelazzo, S., Ferreri, A.J.M., Ambrosetti, A., Martelli, M., Thiéblemont, C., Moreno, H. Gomez, Pinotti, G., Martinelli, G., Mozzana, R., Grisanti, S., Provencio, M., Balzarotti, M., Laveder, F., Oltean, G., Callea, V., Roy, P., Cavalli, F., and Gospodarowicz, M.K.

Published
2003

18. Expression of Cell Differentiation Antigens as a Prognostic Factor in Acute Leukemia

Author

Hołowiecki, J., Lutz, D., Callea, V., Brugiatelli, M., Krzemień, S., Stella-Hołowiecka, B., Neri, A., Ihle, R., Schranz, V., Graf, F., Kelenyi, G., Jagoda, K., Zintl, F., Reves, T., Kardos, G., Barceanu, S., Neth, Rolf, editor, Gallo, Robert C., editor, Greaves, Melvyn F., editor, Gaedicke, Gerhard, editor, Gohla, Sven, editor, Mannweiler, Klaus, editor, and Ritter, Jörg, editor

Published
1989
Full Text
View/download PDF

19. Expression of CD-15 Antigen on Leukemic Cells — A New Prognostic Factor for Ability to Achieve Complete Remission and for Survival in ANLL

Author

Hołowiecki, J., Lutz, D., Krzemień, S., Graf, F., Keleney, G., Brugiatelli, M., Callea, V., Hołowiecka, B., Jagoda, K., Ihle, R., Krč, I., Heimpel, H., editor, Huhn, D., editor, Mueller-Eckhardt, C., editor, Ruhenstroth-Bauer, G., editor, Büchner, T., editor, Schellong, G., editor, Hiddemann, W., editor, Urbanitz, D., editor, and Ritter, J., editor

Published
1987
Full Text
View/download PDF

20. A recent update of 3 consecutive prospective trials with high-dose therapy and autograft, without or with rituximab, as primary treatment for advanced-stage follicular lymphoma shows a sizeable group of patients surviving in continuous complete remission

Author

Tarella C, Ladetto M, Benedetti F, Vitolo U, Pulsoni A, Patti C, Callea V, Rambaldi A, Piccin A, Devizzi L, Musso M, Iannitto E, Spedini P, Liberati AM, Gallamini A, Rodeghiero F, Gini G, De Crescenzo A, Di Raimondo F, Levis A, Chisesi T, Petrone T, Scalabrini DR, Rossi G, Carella AM, Parvis G, Majolino I, Passera R, Ruella M, Pileri A, Gianni AM, Corradini P., CICERI , FABIO, Tarella, C, Ladetto, M, Benedetti, F, Vitolo, U, Pulsoni, A, Patti, C, Callea, V, Rambaldi, A, Piccin, A, Devizzi, L, Musso, M, Iannitto, E, Spedini, P, Liberati, Am, Ciceri, Fabio, Gallamini, A, Rodeghiero, F, Gini, G, De Crescenzo, A, Di Raimondo, F, Levis, A, Chisesi, T, Petrone, T, Scalabrini, Dr, Rossi, G, Carella, Am, Parvis, G, Majolino, I, Passera, R, Ruella, M, Pileri, A, Gianni, Am, and Corradini, P.

Published
2010

21. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients

Author

Foà, R, Del Giudice, I, Cuneo, Antonio, Del Poeta, G, Ciolli, S, Di Raimondo, F, Lauria, F, Cencini, E, Rigolin, Gian Matteo, Cortelezzi, A, Nobile, F, Callea, V, Brugiatelli, M, Massaia, M, Molica, S, Trentin, L, Rizzi, R, Specchia, G, Di Serio, F, Orsucci, L, Ambrosetti, A, Montillo, M, Luigi Zinzani, P, Ferrara, F, Morabito, F, Angela Mura, M, Soriani, S, Peragine, N, Tavolaro, S, Bonina, S, Marinelli, M, Stefania De Propris, M, Della Starza, I, Piciocchi, A, Alietti, A, Runggaldier, Ej, Gamba, E, Romana Mauro, F, Chiaretti, S, Guarini, A., R. Foà, I. D. Giudice, A. Cuneo, G. D. Poeta, S. Ciolli, F. D. Raimondo, F. Lauria, E. Cencini, G. M. Rigolin, A. Cortelezzi, F. Nobile, V. Callea, M. Brugiatelli, M. Massaia, S. Molica, L. Trentin, R. Rizzi, G. Specchia, F. D. Serio, L. Orsucci, A. Ambrosetti, M. Montillo, P. L. Zinzani, F. Ferrara, F. Morabito, M. A. Mura, S. Soriani, N. Peragine, S. Tavolaro, S. Bonina, M. Marinelli, M. S. De, I. D. Starza, A. Piciocchi, A. Alietti, E. J. Runggaldier, E. Gamba, F. R. Mauro, S. Chiaretti, and A. Guarini

Subjects
Male, Murine-Derived, drug therapy/pathology, Male, Survival Analysis, Treatment Outcome, Antibodies, Disease-Free Survival, Drug Administration Schedule, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Monoclonal, 80 and over, 80 and over, Antibodie, Humans, therapeutic use, Chlorambucil, Chronic, Aged, Aged, 80 and over, Aged, Aged, Leukemia, Chlorambucil, Female, Induction Chemotherapy, Leukemia, Lymphocytic, Chronic, B-Cell, Rituximab, Survival Analysis, Treatment Outcome, Hematology, B-Cell, Lymphocytic, CLL, chlorambucil, administration /&/ dosage, Antineoplastic Combined Chemotherapy Protocol, administration /&/ dosage, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Induction Chemotherapy, Leukemia, Settore MED/15 - Malattie del Sangue
Abstract

In a phase II trial, we evaluated chlorambucil and rituximab (CLB-R) as first-line induction treatment with or without R as maintenance for elderly chronic lymphocytic leukemia (CLL) patients. Treatment consisted of eight 28-day cycles of CLB (8 mg/m(2) /day, days 1-7) and R (day 1 of cycle 3, 375 mg/m(2) ; cycles 4-8, 500 mg/m(2) ). Responders were randomized to 12 8-week doses of R (375 mg/m(2) ) or observation. As per intention-to-treat analysis, 82.4\% (95\% CI, 74.25-90.46\%) of 85 patients achieved an overall response (OR), 16.5\% a complete response (CR), 2.4\% a CR with incomplete bone marrow recovery. The OR was similar across Binet stages (A 86.4\%, B 81.6\%, and C 78.6\%) and age categories (60-64 years, 92.3\%; 65-69, 85.2\%; 70-74, 75.0\%; ≥75, 81.0\%). CLB-R was well tolerated. After a median follow-up of 34.2 months, the median progression-free survival (PFS) was 34.7 months (95\% CI, 33.1-39.5). TP53 abnormalities, complex karyotype, and low CD20 gene expression predicted lack of response; SF3B1 mutation and BIRC3 disruption low CR rates. IGHV mutations significantly predicted PFS. R maintenance tended towards a better PFS than observation and was safe and most beneficial for patients in partial response and for unmutated IGHV cases. CLB-R represents a promising option for elderly CLL patients.

Published
2014

22. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial

Author

Palumbo, A, Bringhen, S, Liberati, Anna Marina, Caravita, T, Falcone, A, Callea, V, Montanaro, M, Ria, R, Capaldi, A, Zambello, R, Benevolo, G, Derudas, D, Dore, F, Cavallo, F, Gay, F, Falco, P, Ciccone, G, Musto, P, Cavo, M, Boccadoro, M., for the Italian Multiple Myeloma Network GIMEMA, Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, MontanaroM, Ria R, Capaldi A, Zambello R, Benevolo G, Derudas D, Dore F, Cavallo F, Gay F, Falco P, Ciccone G, Musto P, Cavo M, and Boccadoro M.

Subjects
Melphalan, Oncology, medicine.medical_specialty, Immunology, BORTEZOMIB, Administration, Oral, PLUS THALIDOMIDE, Biochemistry, Disease-Free Survival, chemistry.chemical_compound, Prednisone, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Multiple myeloma, Aged, Aged, 80 and over, Intention-to-treat analysis, business.industry, Bortezomib, Surrogate endpoint, Age Factors, STAGING SYSTEM, DEXAMETHASONE, Cell Biology, Hematology, Middle Aged, medicine.disease, Nitrogen mustard, Thalidomide, Methotrexate, Treatment Outcome, chemistry, Cisplatin, Multiple Myeloma, business, Follow-Up Studies, medicine.drug
Abstract

The initial analysis of the oral combination melphalan, prednisone, and thalidomide (MPT) in newly diagnosed patients with myeloma showed significantly higher response rate and longer progression-free survival (PFS) than did the standard melphalan and prednisone (MP) combination and suggested a survival advantage. In this updated analysis, efficacy and safety end points were updated. Patients were randomly assigned to receive oral MPT or MP alone. Updated analysis was by intention to treat and included PFS, overall survival (OS), and survival after progression. After a median follow-up of 38.1 months, the median PFS was 21.8 months for MPT and 14.5 months for MP (P = .004). The median OS was 45.0 months for MPT and 47.6 months for MP (P = .79). In different patient subgroups, MPT improved PFS irrespective of age, serum concentrations of β2-microglobulin, or high International Staging System. Thalidomide or bortezomib administration as salvage regimens significantly improved survival after progression in the MP group (P = .002) but not in the MPT group (P = .34). These data confirm activity of MPT for PFS but failed to show any survival advantage. New agents in the management of relapsed disease could explain this finding. The study is registered at www.clinicaltrials.gov as #NCT00232934.

Published
2008

23. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage

Author

Ladetto, M, DE MARCO, F, Benedetti, F, Vitolo, U, Patti, C, Rambaldi, A, Pulsoni, Alessandro, Musso, M, Liberati, Am, Olivieri, A, Gallamini, A, Pogliani, E, Scalabrini, Dr, Callea, V, DI RAIMONDO, F, Pavone, V, Tucci, A, Cortelazzo, S, Levis, A, Boccadoro, M, Majolino, I, Pileri, A, Gianni, Am, Passera, R, Corradini, P, Tarella, C, GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO GITMO, INTERGRUPPO ITALIANO LINFOMI IIL, Foa, Roberto, Ladetto, M, De Marco, F, Benedetti, F, Vitolo, U, Patti, C, Rambaldi, A, Pulsoni, A, Musso, M, Liberati, A, Olivieri, A, Gallamini, A, Pogliani, E, Scalabrini, D, Callea, V, Di Raimondo, F, Pavone, V, Tucci, A, Cortelazzo, S, Levis, A, Boccadoro, M, Majolino, I, Pileri, A, Gianni, A, Passera, R, Corradini, P, and Tarella, C

Subjects
Male, Lymphoma, Follicular lymphoma, Salvage therapy, PREDICTIVE MODEL, Kaplan-Meier Estimate, INDOLENT LYMPHOMA, CHOP, Biochemistry, Gastroenterology, Antibodies, Monoclonal, Murine-Derived, Risk Factors, MED/15 - MALATTIE DEL SANGUE, hemic and lymphatic diseases, BONE-MARROW-TRANSPLANTATION, TERM-FOLLOW-UP, DOSE SEQUENTIAL CHEMOTHERAPY, STEM-CELL TRANSPLANTATION, NON-HODGKINS-LYMPHOMA, PROGRESSION-FREE SURVIVAL, MINIMAL RESIDUAL DISEASE, UNTREATED PATIENTS, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Medicine, Prospective Studies, Treatment Failure, Lymphoma, Follicular, Antibodies, Monoclonal, Hematology, Middle Aged, Rituximab, prognosis, Transplantation, Autologou, Treatment Outcome, Female, Survival Analysi, Immunotherapy, medicine.drug, Human, Adult, medicine.medical_specialty, Adolescent, Immunology, Transplantation, Autologous, Chemoimmunotherapy, Internal medicine, Humans, Proportional Hazards Models, Salvage Therapy, Antineoplastic Combined Chemotherapy Protocol, business.industry, Risk Factor, Cell Biology, Phosphamide, medicine.disease, Survival Analysis, Surgery, Transplantation, Feasibility Studie, Prospective Studie, Proportional Hazards Model, Feasibility Studies, business
Abstract

In this randomized multicenter study of 136 patients, 6 courses of CHOP (cyclo-phosphamide/doxorubicin/vincristine/prednisone) followed by rituximab (CHOP-R) were compared with rituximab-supplemented high-dose sequential chemotherapy with autografting (R-HDS) to assess the value of intensified chemo-therapy as a first-line treatment for high-risk follicular lymphoma (FL) after the introduction of monoclonal antibodies. The analysis was intention to treat with event-free survival (EFS) as the primary endpoint. Complete remission (CR) was 62% with CHOP-R and 85% with R-HDS (P < .001). At a median follow-up (MFU) of 51 months, the 4-year EFS was 28% and 61%, respectively (P < .001), with no difference in overall survival (OS). Molecular remission (MR) was achieved in 44% of CHOP-R and 80% of R-HDS patients (P < .001), and was the strongest independent outcome predictor. Patients relapsing after CHOP-R underwent salvage R-HDS in 71% of cases. Salvage R-HDS had an 85% CR rate and a 68% 3-year EFS (MFU, 30 months). We conclude that (1) achieving MR is critical for effective disease control, regardless of which treatment is used; (2) R-HDS ensures superior disease control and molecular outcome than CHOP-R, but no OS improvement; and (3) CHOP-R failures have a good outcome after salvage R-HDS, suggesting that relapsed/refractory FL could be the most appropriate setting for R-HDS–like treatments. This trial was registered at www.clinicaltrials.gov as no. NCT00435955.

Published
2008

24. Splenic marginal zone lymphoma: A prognostic model for clinical use

Author

Arcaini, L, Lazzarino, M, Colombo, N, Burcheri, S, Boveri, E, Paulli, M, Morra, E, Gambacorta, M, Cortelazzo, S, Tucci, A, Ungari, M, Ambrosetti, A, Menestrina, F, Orsucci, L, Novero, D, Pulsoni, A, Frezzato, M, Gaidano, G, Vallisa, D, Minardi, V, Tripodo, C, Callea, V, Baldini, L, Merli, F, Federico, Massimo, Franco, V, Iannitto, E, INTEGRUPPO ITALIANO LINFOMI, Arcaini, L., Lazzarino, M., Colombo, N., Burcheri, S., Boveri, E., Paulli, M., Morra, E., Gambacorta, M., Cortelazzo, S., Tucci, A., Ungari, M., Ambrosetti, A., Menestrina, F., Orsucci, L., Novero, D., Pulsoni, A., Frezzato, M., Gaidano, G., Vallisa, D., Minardi, V., Tripodo, C., Callea, V., Baldini, L., Merli, F., Federico, M., Franco, V., and Iannitto, E.

Subjects
Male, splenic marginal zone lymphoma, prognostic factors, International Prognostic Index (IPI), VILLOUS LYMPHOCYTES, Hydro-Lyase, B-CELL, Longitudinal Studie, Predictive Value of Test, Biochemistry, Gastroenterology, Hemoglobins, chemistry.chemical_compound, International Prognostic Index, Risk Factors, BONE-MARROW INFILTRATION, NON-HODGKINS-LYMPHOMA, C VIRUS-INFECTION, Age Factor, Longitudinal Studies, Multivariate Analysi, Aged, 80 and over, Univariate analysis, Hematology, Mortality rate, Age Factors, Middle Aged, Prognosis, Splenic Neoplasm, Survival Rate, Predictive value of tests, Human, Adult, medicine.medical_specialty, Lymphoma, B-Cell, Prognosi, Immunology, Disease-Free Survival, Predictive Value of Tests, Albumins, Internal medicine, Lactate dehydrogenase, Aged, Humans, Hydro-Lyases, Multivariate Analysis, Platelet Count, Splenic Neoplasms, Models, Theoretical, medicine, Hemoglobin, Splenic marginal zone lymphoma, Survival rate, business.industry, Albumin, Risk Factor, Cell Biology, medicine.disease, Surgery, chemistry, business
Abstract

The Integruppo Italiano Linfomi (IIL) carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in 309 patients. The 5-year cause-specific survival (CSS) rate was 76%. In univariate analysis, the parameters predictive of shorter CSS were hemoglobin levels below 12 g/dL (P < .001), albumin levels below 3.5 g/dL (P = .001), International Prognostic Index (IPI) scores of 2 to 3 (P < .001), lactate dehydrogenase (LDH) levels above normal (P < .001), age older than 60 years (P = .01), platelet counts below 100 000/μL (P = .04), HbsAg-positivity (P = .01), and no splenectomy at diagnosis (P = .006). Values that maintained a negative influence on CSS in multivariate analysis were hemoglobin level less than 12 g/dL, LDH level greater than normal, and albumin level less than 3.5 g/dL. Using these 3 variables, we grouped patients into 3 prognostic categories: low-risk group (41%) with no adverse factors, intermediate-risk group (34%) with one adverse factor, and high-risk group (25%) with 2 or 3 adverse factors. The 5-year CSS rate was 88% for the low-risk group, 73% for the intermediate-risk group, and 50% for the high-risk group. The cause-specific mortality rate (x 1000 person-years) was 20 for the low-risk group, 47 for the intermediate-risk group, and 174 for the high-risk group. This latter group accounted for 54% of all lymphoma-related deaths. In conclusion, with the use of readily available factors, this prognostic index may be an effective tool for evaluating the need for treatment and the intensity of therapy in an individual patient. © 2006 by The American Society of Hematology.

Published
2006

25. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

Author

Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P, Boccadoro M, Italian Multiple Myeloma Network, GIMEMA, ZAMAGNI, ELENA, Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P, Boccadoro M, Italian Multiple Myeloma Network, and GIMEMA.

Subjects
Melphalan, Male, medicine.medical_specialty, Antineoplastic Agents, Hormonal, Hormonal Antineoplastic Combined Chemotherapy Protocols Disease-Free Survival Melphalan Multiple Myeloma/drug therapy Multiple Myeloma/mortality Prednisone Thalidomide, medicine.medical_treatment, anticoagulant agent, Gastroenterology, Disease-Free Survival, Aged Antineoplastic Agents, Prednisone, Internal medicine, thalidomide, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, Alkylating Antineoplastic Agents, Antineoplastic Agents, Alkylating, Multiple myeloma, antineoplastic agent, Antibacterial agent, Aged, Aged, 80 and over, Chemotherapy, business.industry, Hazard ratio, enoxaparin, General Medicine, Middle Aged, medicine.disease, Surgery, melphalan, Thalidomide, prednisone, Female, business, Multiple Myeloma, Progressive disease, medicine.drug
Abstract

Summary Background Since 1960, oral melphalan and prednisone (MP) has been regarded as the standard of care in elderly multiple myeloma patients. This multicentre randomised trial compared oral MP plus thalidomide (MPT) with MP alone in patients aged 60–85 years. Methods Patients with newly diagnosed multiple myeloma were randomly assigned to receive oral MP for six 4-week cycles plus thalidomide (n=129; 100 mg per day continuously until any sign of relapse or progressive disease) or MP alone (n=126). Analysis was intention-to-treat. This study is registered at ClinicalTrial.gov, number NCT00232934. Results Patients treated with thalidomide had higher response rates and longer event-free survival (primary endpoints) than patients who were not. Combined complete or partial response rates were 76·0% for MPT and 47·6% for MP alone (absolute difference 28·3%, 95% CI 16·5–39·1), and the near-complete or complete response rates were 27·9% and 7·2%, respectively. 2-year event-free survival rates were 54% for MPT and 27% for MP (hazard ratio [HR] for MPT 0·51, 95% CI 0·35–0·75, p=0·0006). 3-year survival rates were 80% for MPT and 64% for MP (HR for MPT 0·68, 95% CI 0·38–1·22, p=0·19). Rates of grade 3 or 4 adverse events were 48% in MPT patients and 25% in MP patients (p=0·0002). Introduction of enoxaparin prophylaxis reduced rate of thromboembolism from 20% to 3% (p=0·005). Conclusion Oral MPT is an effective first-line treatment for elderly patients with multiple myeloma. Anticoagulant prophylaxis reduces frequency of thrombosis. Longer follow-up is needed to assess effect on overall survival.

Published
2006

28. Presenting features and outcome of Splenic Marginal Zone Lymphoma with or without villous lymphocytes. A retrospective analysis in a Series of 145 Patients

Author

IANNITTO E, AMBROSETTI A, CALLEA V, STELITANO C, TRIPODO, Claudio, CALVARUSO G, MITRA ME, PATTI K, PIZZOLO G., FLORENA, Ada Maria, MINARDI, Viviana Maria, DE CANTIS, Stefano, ABBADESSA, Vincenzo, IANNITTO E, AMBROSETTI A, CALLEA V, STELITANO C, FLORENA A, TRIPODO C, MINARDI V, CALVARUSO G, MITRA ME, DE CANTIS S, PATTI K, ABBADESSA V, and PIZZOLO G

Published
2004

30. An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients

Author

Cortelezzi, A, Gritti, G, Laurenti, L, Cuneo, Antonio, Ciolli, S, Di Renzo, N, Musto, P, Mauro, Fr, Cascavilla, N, Falchi, L, Zallio, F, Callea, V, Maura, F, Martinelli, S, Piciocchi, A, Reda, G, Foà, R, and on behalf of the GIMEMA Chronic Lymphoproliferative Disorders Working Party

Subjects
Chronic lymphocytic leukaemia, Alemtuzumab, Infection, Monoclonal antibodies
Published
2012

33. A PHASE II STUDY OF CHLORAMBUCIL+RITUXIMAB (CLB-R) FOLLOWED BY R MAINTENANCE VS OBSERVATION IN ELDERLY PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INDUCTION PHASE RESULTS

Author

Foa, R., Alietti, A., Guarini, A., Ciolli, S., Di Raimondo, F., Del Poeta, G., Lauria, F., Forconi, F., Antonio Cuneo, Cortellezzi, A., Nobile, F., Callea, V., Brugiatelli, M., Massaia, M., Molica, S., Trentin, L., Rizzi, R., Specchia, G., Orsucci, L., Ambrosetti, A., Montillo, M., Zinzani, L., Ferrara, F., Morabito, F., Marco Mura, Soriani, S., Santangelo, S., Marinelli, M., Propris, M., and Runggaldier, J.

Published
2011

36. LENALIDOMIDE PLUS LOW DOSE DEXAMETHASONE AS FIRST LINE THERAPY IN PATIENTS WITH PRIMARY PLASMA CELL LEUKEMIA: PLANNED INTERIM ANALYSIS OF A PILOT STUDY FROM THE GIMEMA-ITALIAN MYELOMA NETWORK

Author

Musto, P., D'Auria, F., Petrucci, Mt, Morabito, F., Nobile, F., Offidani, M., DI RAIMONDO, Francesco, Falcone, A., Lerose, R., Zifarone, E., Zonno, A., Callea, V., Levi, A., Mazzone, C., Pietrantuono, G., Martorelli, M., Villani, O., Guariglia, R., Mansueto, G., Grieco, V., Bianchino, G., Neri, A., Todoerti, K., Omedè, P., Bringhen, S., Cavo, M., Boccadoro, M., and Palumbo, A.

Published
2010

37. Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (Gruppo Italiano Studio Linfomi) Trial

Author

Molica, Fabris, S., Cutrona, G., Matis, S., Pesce, E. A., Maura, F., Di Raimondo, G. Ciceri F., Musolino, C., Gobbi, M., Di Renzo, N., Romana Mauro, F., Cantaffa, R., Brugiatelli, M., Merli, F., Zupo, S., Mammi, C., Baldini, L., Angrilli, F., Quintana, G., Consoli, U., Iannitto, E., Di Tonno, P., Fragasso, A., Pellegrino, Musto, Cox, M. C., Festini, G., Callea, V., Sacchi, Stefano, Cortelezzi, A., Lambertenghi Deliliers, G., Foà, R., Federico, Massimo, Neri, A., Ferrarini, M., and Morabito, F.

Subjects
CLL
Published
2010

41. A PROSPECTIVE RANDOMIZED TRIAL OF BORTEZOMIB-MELPHALANPREDNISONE-THALIDOMIDE FOLLOWED BY CONTINUOUS BORTEZOMIB-THALIDOMIDE FOR INITIAL THERAPY OF MULTIPLE MYELOMA:EFFECT OF AGE AND CO-MORBIDITIES

Author

Palumbo, Antonio, Bringhen, S., Rossi, D., Cavalli, M., Ria, R., Offidani, M., Nozzoli, C., Baldini, L., De Rosa, L., De Sabbata, G., Liberati, Am, Crippa, C., Ciambelli, F., Callea, V., Spriano, M., Ferrara, F., Elice, F., Galli, M., Peccatori, J., Catalano, L., Rizzo, M., Marasca, R., Pisani, F., Cavo, M., Petrucci, M., Musto, P., Omedè, P., Larocca, Alessandra, Gaidano, G., and Boccadoro, Mario

Published
2010

43. ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN 895 ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF 3 MULTICENTER ITALIAN TRIALS

Author

Gay, F., Larocca, A., Petrucci, Mt, Musto, P., Liberati, Am, Callea, V., Ria, R., Caravita, T., Cangialosi, C., Grasso, M., Offidani, M., Pregno, P., Patriarca, F., Galli, M., Cavo, M., Catalano, L., Nozzoli, C., Guglielmelli, T., Zambello, R., Pisani, F., Montefusco, V., Rossini, F., DE STEFANO, V., Lupo, B., DI RAIMONDO, Francesco, Gaidano, G., Boccadoro, M., and Palumbo, A.

Published
2010

44. A Prospective Randomized Trial of Bortezomib-melphalan-prednisone-thalidomide Followed By Continuous Bortezomib-thalidomide For Initial Therapy of Multiple Myeloma: Effect of Age and Co-morbidities

Author

Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Ria, R., Offidani, M., Nozzoli, C., Baldini, L., Rosa, L. D., Sabbata, G. D., Liberati, Anna Marina, Crippa, C., Ciambelli, F., Callea, V., Spriano, M., Ferrara, F., Elice, F., Galli, M., Peccatori, J., Catalano, L., Rizzo, M., Marasca, R., Pisani, F., Cavo, M., Petrucci, M., Musto, P., Omede, P., Larocca, A., Gaidano, G., and Boccadoro, M.

Published
2010

45. Bortezomib, Melphalan, Prednisone and Thalidomide (vmpt) Versus Bortezomib, Melphalan and Prednisone (vmp) In Elderly Newly Diagnosed Myeloma Patients: A Prospective, Randomized, Phase Iii Study

Author

Palumbo, A., Bringhen, S., Rossi, D., Ria, R., Berretta, S., Offidani, M., Patriarca, F., Nozzoli, C., Levi, A., Guglielmelli, T., Benevolo, G., Callea, V., Liberati, Anna Marina, Crippa, C., Renzo, N. D., Catalano, L., Sabbata, G. D., Rizzi, R., Feo, C., Mazza, R., Farina, G., Spadano, A., Pisani, F., Podda, L., Aitoro, G., Magarotto, V., Astolfi, M., Raimondo, F. D., Gaidano, G., and Boccadoro, M.

Published
2009

46. Superior complete response rate and progression-free survival after autologous stem-cell transplantation (ASCT) incorporating velcade-thalidomide-dexamethasone (VTD)compared to thalidomide-dexametha-sone (TD) in newly diagnosed multiple myelona

Author

Cavo, M, Pantani, L, Patriarca, F, Petrucci, M. T., Tacchetti, P, Galli, L, DI RAIMONDO, Francesco, Crippa, C, Bringhen, S, Montefusco, V, Narni, F, Offidani, M, Spadano, T, Olivero, B, Pescosta, N, Caravita, T, Cellini, C, Ledda, A, Falcone, A, Agostini, P, Cavraro, M, Masini, L, Nozzoli, C, Ballanti, S, Derudas, D, DE STEFANO, V, Pisani, F, Califano, C, Callea, V, Catania, G, Nozza, A, Palmieri, S, Peccatori, J, Baraldi, A, Fattori, Pp, Pasini, S, Musto, P, Grasso, M, Ballerini, F, Cangialosi, C, Catalano, L, Morandi, S, Ronconi, S, and Baccarani, M.

Published
2009

47. PERIPHERAL NEUROPATHY IN BORTEZOMIB, MELPHALAN, PREDNISONE AND THALIDOMIDE (VMPT) VERSUS BORTEZOMIB, MELPHALAN AND PREDNISONE (VMP):IMPACT OF LOW-DOSE THALIDOMIDE AND WEEKLY INFUSION OF BORTEZOMIB

Author

Genuardi, M, Bringhen, S, Rossi, D, Ria, R, Offidani, M, Patriarcaf, GUGLIELMELLI T, NOZZOLI C. LEVI A., Pregno, P, Callea, V, Pescosta, N, Mele, A, Giuliani, N, Mele, G, Capaldi, A, Dominietto, A, Rossini, F, Gherlinzoni, F, Baraldi, A, DI RAIMONDO, Francesco, Boccadoro, M, and Palumbo, A.

Published
2009

48. DIAGNOSTIC POTENTIAL OF CD38 COMBINED WITH ZAP70 EXPRESSION IN PREDICTING MUTATIONAL STATUS OF IMMUNOGLOBULIN HEAVY-CHAIN VARIABLE REGION IN CHRONIC LYMPHOCYTIC LEUKEMIA: PRELIMINARY RESULTS OF A PROSPECTIVE, MULTICENTER O-CLL1- GISL STUDY

Author

Gentile, M., Cutrona, G., Matis, S., Fabris, S., Pedemonte, S., Pesce, E. A., Di Raimondo, F., Musolino, C., Gobbi, M., Di Renzo, N., Mauro, Francesca Romana, Cantaffa, R., Brugiatelli, M., Merli, F., Zupo, S., Mammi, C., Baldini, L., Angrilli, F., Quintana, G., Consoli, U., Bertoldero, G., Iannitto, E., Di Tonno, P., Fragasso, A., Molica, S., Musto, P., Cox, M. C., Festini, G., Callea, V., Sacchi, S., Cortelezzi, A., Foa, Roberto, Federico, M., Neri, A., Ferrarini, M., and Morabito, F.

Published
2009

49. INCIDENCE OF CYTOGENETIC ABNORMALITIES IN NEWLY DIAGNOSED BINET STAGE A B-CLL AND RELATIONSHIP WITH PROGNSOTIC BIOMARKERS: PRELIMINARY RESULTS ON 240 PATIENTS INCLUDED IN THE PROSPECTIVE, MULTICENTER O-CLL1 GISL STUDY

Author

Fabris, S, Cutrona, G, Gentile, M, Matis, S, Pesce, E. A., DI RAIMONDO, Francesco, Musolino, C, Gobbi, M, DI RENZO, N, Mauro, F. R., Cantaffa, R, Brugiatelli, M, Merli, F, Zupo, S, Mammi, C, Baldini, L, Angrilli, F, Quintana, G, Consoli, U, Bertoldero, G, Iannitto, E, DI TONNO, P, Fragasso, A, Molica, S, Musto, P, Cox, M. C., Festini, G, Callea, V, Sacchi, S, Cortellezzi, A, LAMBERTENGHI DELILIERS, G, FEDERICO M, FOÀ R., Ferrarini, M, Morabito, F, and Neri, A.

Published
2009

50. BORTEZOMIB, MELPHALAN, PREDNISONE AND THALIDOMIDE (VMPT)VERSUS BORTEZOMIB, MELPHALAN AND PREDNISONE (VMP) INELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS: A PROSPECTIVE,RANDOMIZED, PHASE III STUDY

Author

Palumbo, Antonio, Bringhen, S., Rossi, D., Ria, R., Berretta, S., Offidani, M., Patriarca, F., Nozzoli, C., Levi, A., Guglielmelli, T., Benevolo, G., Callea, V., Liberati, A. M., Crippa, C., Di Renzo, N., Catalano, L., De Sabbata, G., Rizzi, R., Feo, C., Mazza, R., Farina, G., Spadano, A., Pisani, F., Podda, L., Aitoro, G., Magarotto, V., Astolfi, M., Di Raimondo, F., Gaidano, G., and Boccadoro, Mario

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results